The United Kingdom’s Competition and Markets Authority has closed an investigation into an alleged anticompetitive discount scheme related to brand-name infliximab, Remicade.
The United Kingdom’s Competition and Markets Authority (CMA) has closed an investigation into an alleged anticompetitive discount scheme related to brand-name infliximab, Remicade.
Merck Sharp & Dhome (which is known as MSD outside of the United States and Canada, and which is not to be confused with Merck KGaA, a separate company) sells the brand-name infliximab in the United Kingdom. MSD was suspected of engaging in discounting practices that were designed to block biosimilar infliximab products from competing in the nation’s healthcare system, and an investigation into the matter was opened in 2015.
According to the CMA, by linking the level of discount offered on the brand-name drug to the total amount of the product purchased, MSD purportedly attempted to dissuade the UK National Health Service (NHS) from switching to biosimilars that could have provided substantial savings on the NHS’ infliximab spending of approximately £100 million (approximately US $130 million).
According to a statement made on Thursday, while the CMA found in 2017 that MSD was in breach of competition law, it has now decided that there are no grounds for the agency to take action against MSD because the drug company’s scheme was largely unsuccessful in blocking biosimilars from NHS uptake.
“The CMA case decision group has concluded that MSD’s scheme was not, in practice, likely to limit competition from others—the legal test for finding MSD’s conduct to be unlawful,” the agency said in a statement. However, it added that “CMA’s investigation serves as a warning to businesses which design discount schemes to protect their dominant market position, that they risk breaching UK competition law: had MSD’s scheme in practice been likely to prevent or limit competition from rivals, the company could have faced severe financial penalties.”
In an email to The Center for Biosimilars®, an MSD representative said that "MSD has always maintained that the discount was not intended to restrict competition and we are pleased that the CMA has now concluded that there are No Grounds for Action. The discount referred to was developed to ensure Remicade was competitively priced, offered substantial savings to the UK National Health Service and in doing so provided greater budgetary certainty to the NHS."
The case is particularly notable because MSD, in addition to commercializing Remicade in the UK market, also commercializes biosimilars; in the United States, the company is responsible for selling Renflexis, a biosimilar infliximab developed by Samsung Bioepis that competes with Remicade (although the drug is marketed by Biogen in the EU under the name Flixabi).
The end of the investigation comes just weeks after a Canadian investigation into alleged anticompetitive practices related to Remicade was also closed.
The Canadian case involved Janssen, a division of Johnson & Johnson, which sells the brand-named Remicade in Canada, the United States, and other markets. Canada’s Competition Bureau found that Janssen did in fact engage in a number of anticompetitive practices, such as negotiating exclusive contracts that barred biosimilars, but that there was not sufficient evidence to demonstrate that the company’s conduct had effectively blocked biosimilars.
This article has been updated to include MSD's statement.
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.
Experts Pressure Congress to Remove Roadblocks for Biosimilars
April 12th 2025Lawmakers and expert witnesses emphasized the potential of biosimilars to lower health care costs by overcoming barriers like pharmacy benefit manager practices, limited awareness, and regulatory delays to improve access and competition in chronic disease management during a recent congressional hearing.